✉news ScienceScience first seen 13 h ago, last 10 h ago, peak #15
Kodiak Stock Soars 183% on Eye Drug Advances
Original: Kodiak Stock Gains 183% as New Eye Drugs Take Aim at Regeneron’s Eylea
Kodiak Sciences' stock has surged 183%, with its new eye drugs seen as direct challengers to Regeneron's blockbuster Eylea, a leading treatment for retinal conditions. The rally marks a dramatic turnaround for the biotech as investors bet its therapies could capture a share of the highly lucrative eye-disease market currently dominated by Regeneron.
Why now: A dramatic 183% stock surge tied to competition against a blockbuster drug is drawing investor attention.
Rank over time, top of the chart is #1. 3 snapshots from 13 h ago to 10 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/994326